Vol. 20 No. 2 (2021)
Original Articles

Tracking the history of circulating nucleic acids for cancer research in Brazil: A systematic review

PDF
  • Mariana Chantre-Justino,
  • Lucas Delmonico,
  • Claudia Lage,
  • Maria G. C. Carvalho,
  • Maria Helena F. Ornellas,
  • Gilda Alves
DOI: https://doi.org/10.12957/bjhbs.2021.63966

Published 2022-01-04

Keywords

  • Brazil,
  • Cancer,
  • Circulating nucleic acids,
  • cfDNA,
  • cfRNA,
  • Liquid biopsy
    • ...More
    Less

How to Cite

1.
Chantre-Justino M, Delmonico L, Lage C, G. C. Carvalho M, F. Ornellas MH, Alves G. Tracking the history of circulating nucleic acids for cancer research in Brazil: A systematic review. BJHBS [Internet]. 2022 Jan. 4 [cited 2024 Nov. 21];20(2):135-43. Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/36

Copyright (c) 2021 Brazilian Journal of Health and Biomedical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Introduction: Circulating nucleic acids can be obtained by minimally invasive procedures based on liquid biopsy, which has emerged as a promising area of investigation for screening and monitoring cancer treatment. Currently, tests based on circulating nucleic acid analysis, specifically cell-free DNA (cfDNA), are commercially available for diagnostic and prognostic investigation of a number of neoplasms. Ob-jective: To describe the research on circulating nucleic acid markers for cancer prospecting in Brazil, since this area has advanced rapidly in recent years. Methods: In this systematic review, we surveyed Brazilian publications in cancer research focused on cfDNA and cfRNA present in different fluids. Both MEDLINE-PUBMED and EMBASE databases were inspected using terms such as “circulating nucleic acids”, “cancer”, and “Brazil”. Results: The search returned 326 articles, in which 28 Brazilian translational studies were eligible. Different methodologies were reported for different types of cancer, in which cfDNA from plasma was the most investigated biological material. Molecular investigations included quan-tification, somatic mutation, RNA expression, genotyping, microsatellites, blood protein interaction, and methylation. Discrepancies in the regional distribution of the studies were also observed. Conclusion: Studies on circulating nucleic acid markers have advanced significantly in the oncology field, but many others are needed to better address the clinical practice in Brazil.

PDF

Metrics

Metrics Loading ...

References

  1. Shyr D, Liu Q. Next generation sequencing in cancer research and clinical application. Biol Proced Online. 2013;15(1):4. DOI: 10.1186/1480-9222-15-4
  2. Castro-Giner F, Gkountela S, Donato C, et al. Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. Diagnostics (Basel). 2018;8(2):31. DOI: 10.3390/diagnostics8020031
  3. Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. DOI: 10.1016/j. bdq.2019.100087
  4. Delmonico L, Alves G, Bines J. Cell free DNA biology and its involvement in breast carcinogenesis. Adv Clin Chem, 1st ed., Elsevier, 2020;p.171-223. DOI: 10.1016/bs.acc.2019.12.006
  5. Kawamura MT, Paschoal ME, Carvalho MDC. In vitro interaction of serum protein with circulating DNA of lung cancer patient. Int J Mol Med. 1999;4(2):187-190. DOI: 10.3892/ijmm.4.2.187
  6. Kawamura MT, Paschoal ME, Carvalho MDC. Profile of Proteins Complexed with Circulating DNA of a Lung Cancer Patient. Ann N Y Acad Sci. 2006;906:51-54. DOI: 10.1111/j.1749-6632.2000.tb06590.x
  7. Fernández-Lázaro D, Hernández JLG, García AC, et al. Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers. Diagnostics. 2020;10:215. DOI: 10.3390/diagnostics10040215
  8. Alves G, Kawamura MT, Nascimento P, et al. DNA release by line-1 (L1) retrotransposon. Could it be possible? Ann N Y Acad Sci. 2000;906:129-133. DOI: 10.1111/j.1749-6632.2000. tb06602.x
  9. Machado ASC, Robaina MCS, Rezende LMM, et al. Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas. Leuk Lymphoma.2010;51(6):1020-1027. DOI: 10.3109/10428191003746331
  10. Moreno R, Delgado PO, Coelho PG, et al. Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer. Int Arch Med. 2013;6(1):2. DOI: 10.1186/1755-7682-6-2
  11. Delgado PO, Alves BCA, Gehrke FS, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2013;34(2):983-6. DOI: 10.1007/s13277- 012-0634-6
  12. Wroclawski ML, Serpa-Neto A, Fonseca FLA, et al. Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biol. 2013;34(5):2921-2927. DOI: 10.1007/s13277-013-0854-4
  13. Filho BFS, Gurgel APAD, Neto MAFLN, et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol. 2013;66(9):775-778. DOI: 10.1136/jclinpath-2013-201521
  14. Almeida EFP, Abdalla TE, Arrym TP, et al. Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma. Clin Biochem. 2016;49(16-17):1274-1277. DOI: 10.1016/j.clinbiochem.2016.08.021
  15. Faria G, Silva E, Fonseca C, et al. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy. Int J Mol Sci. 2018;19(6):1610. DOI: 10.3390/ijms19061610
  16. Normando SRC, Delgado PO, Rodrigues AKSB, et al. Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy. BMC Clin Pathol. 2018;18:12. DOI: 10.1186/s12907-018-0079-y
  17. Alves SIPMN, Hallack ML, Perez MM, et al. Application of the Z-scan technique for the detection of CFCDNA (cell-free circulating DNA) and urine DNA (uDNA) in patients with bladder cancer. Photodiagnosis Photodyn Ther. 2019;26:131-133. DOI: 10.1016/j.pdpdt.2019.02.022
  18. Alves MC, Fonseca FLA, Yamada AMTD, et al. Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study. Tumour Biol. 2020;42(5):1010428320919198. DOI: 10.1177/1010428320919198
  19. Hyun MH, Sung JS, Kang EJ, et al. Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Oncotarget. 2017;8(55):94417–94430. DOI: 10.18632/oncotarget.21769
  20. Meddeb R, Dache ZAA, Thezenas S, et al. Quantifying circulating cell-free DNA in humans. Sci Rep. 2019;9(1):5220. DOI: 10.1038/s41598-019-41593-4
  21. Carpinetti P, Donnard E, Bettoni F, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–38371. DOI: 10.18632/oncotarget.5256
  22. Ferreira EN, Barros BDF, Souza JE, et al. A genomic case study of desmoplastic small round cell tumor: comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease. Hum Genomics. 2016;10(1):36. DOI: 10.1186/s40246- 016- 0092-0
  23. Knebel FH, Bettoni F, Shimada AK, et al. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer. 2017;108:238-241. DOI: 10.1016/j.lungcan.2017.04.004
  24. Barros BDF, Kupper BEC, Junior SA, et al. Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer. Front Oncol. 2018;8:306. DOI: 10.3389/fonc.2018.00306
  25. Delmonico L, Costa MASM, Fournier MV, et al. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions. Ann Diagn Pathol. 2019;39:30-35. DOI: 10.1016/j.anndiagpath.2018.12.008
  26. Knebel FH, Bettoni F, Fonseca LG, et al. Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer. Front Oncol. 2019;9:170. DOI: 10.3389/fonc.2019.00170
  27. Pizzi MP, Bartelli TF, Pelosof AG, et al. Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow-up. Int J Cancer. 2019;145(4):1090-1098. DOI: 10.1002/ijc.32217
  28. Miguez ACK, Barros BDF, Souza JES, et al. Assessment of somatic mutations in urine and plasma of Wilms tumor patients. Cancer Med. 2020;9(16):5948-5959. DOI: 10.1002/cam4.3236
  29. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257.
  30. Nunes DN, Kowalski LP, Simpson AJ. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas. Int J Cancer. 2001;92(2):214- 219. DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1176>3.0.co;2-c
  31. Pinto JLF, Fonseca FLA, Marsicano SR, et al. Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine. J Pharm Pharmacol. 2010;62(7):931-934. DOI: 10.1211/jpp.62.07.0015
  32. Chantre-Justino M, Alves G. Genetic Polymorphism of Glutathione S-Transferase. In: Pál Perjési. (Org.). Glutathione Biosynthesis, Functions and Biological Implications. 1ed. New York: Nova Science Publishers, 2019; p. 189-222. ISBN: 978-1-53614-740-7
  33. Cabral REC, Caldeira-de-Araujo A, Cabral-Neto JB, et al. Analysis of GSTM1 and GSTT1 polymorphisms in circulating plasma DNA of lung cancer patients. Mol Cell Biochem. 2010;338(1-2):263-269. DOI: 10.1007/s11010-009-0360-6
  34. Silva MM, Fonseca CO, Moura-Neto R, et al. Influence of GSTM1 and GSTT1 polymorphisms on the survival rate of patients with malignant glioma under perillyl alcohol-based therapy. Genet Mol Res. 2013;12(2):1621-1630. DOI: 10.4238/2013.May.14.2
  35. Pezuk JA, Miller TLA, Bevilacqua JLB, et al. Measuring plasma levels of three microRNAs can improve the accuracy for identification of malignant breast lesions in women with BI-RADS 4 mammography. Oncotarget. 2017;8(48):83940-83948. DOI: 10.18632/oncotarget.20806
  36. Souza MF, Kuasne H, Barros-Filho MC, et al. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS One. 2017;12(9):e0184094. DOI: 10.1371/journal.pone.0184094
  37. Llinàs-Arias P, Esteller M. Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biol. 2017;7(9):170152. DOI: 10.1098/rsob.170152
  38. Delmonico L, Costa MASM, Gomes RJ, et al. Methylation profiling in promoter sequences of ATM and CDKN2A (p14ARF/p16INK4a) genes in blood and cfDNA from women with impalpable breast lesions. Oncol Lett. 2020;19(4):3003-3010. DOI: 10.3892/ol.2020.11382
  39. Cui M, Wang H, Yao X, et al. Circulating MicroRNAs in Cancer: Potential and Challenge. Front Genet. 2019;10:626. DOI: 10.3389/fgene.2019.00626

Most read articles by the same author(s)